Hetrombopag + Hetrombopag plus Placebo + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Thrombocytopenia
Conditions
Chemotherapy-Induced Thrombocytopenia
Trial Timeline
Apr 25, 2023 → Sep 1, 2025
NCT ID
NCT05864014About Hetrombopag + Hetrombopag plus Placebo + Placebo
Hetrombopag + Hetrombopag plus Placebo + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Chemotherapy-Induced Thrombocytopenia. The current trial status is active. This product is registered under clinical trial identifier NCT05864014. Target conditions include Chemotherapy-Induced Thrombocytopenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Thrombocytopenia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05864014 | Phase 3 | Active |
Competing Products
20 competing products in Chemotherapy-Induced Thrombocytopenia